Citigroup
AMLX icon

Citigroup’s Amylyx Pharmaceuticals AMLX Stock Holding History

Citigroup’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.04M Sell
35,852
-32,832
-48% -$870K ﹤0.01% 3285
2026
Q2 		$1.23M Buy
68,684
+36,902
+116% +$571K ﹤0.01% 3297
2026
Q1 		$442K Sell
31,782
-6,250
-16% -$87.9K ﹤0.01% 3624
2025
Q4 		$459K Sell
38,032
-51
-0.1% -$693 ﹤0.01% 3614
2025
Q3 		$518K Buy
38,083
+6,985
+22% +$65.7K ﹤0.01% 3554
2025
Q2 		$199K Sell
31,098
-432,142
-93% -$2.1M ﹤0.01% 4065
2025
Q1 		$1.64M Sell
463,240
-146,084
-24% -$520K ﹤0.01% 2882
2024
Q4 		$2.3M Buy
609,324
+34,319
+6% +$161K ﹤0.01% 2701
2024
Q3 		$1.86M Sell
575,005
-88,371
-13% -$199K ﹤0.01% 2735
2024
Q2 		$1.26M Sell
663,376
-251,351
-27% -$487K ﹤0.01% 2734
2024
Q1 		$2.6M Buy
914,727
+527,063
+136% +$6.89M ﹤0.01% 2222
2023
Q4 		$5.71M Buy
387,664
+343,875
+785% +$5.27M ﹤0.01% 1506
2023
Q3 		$802K Sell
43,789
-33,780
-44% -$714K ﹤0.01% 2684
2023
Q2 		$1.67M Buy
77,569
+44,443
+134% +$1.2M ﹤0.01% 2381
2023
Q1 		$972K Buy
33,126
+23,403
+241% +$813K ﹤0.01% 2577
2022
Q4 		$359K Buy
9,723
+1,002
+11% +$35.6K ﹤0.01% 3386
2022
Q3 		$245K Buy
8,721
+7,886
+944% +$197K ﹤0.01% 3687
2022
Q2 		$16K Sell
835
-319
-28% -$3.79K ﹤0.01% 5115
2022
Q1 		$15K Buy
+1,154
New +$26.1K ﹤0.01% 5302

Other funds holding AMLX

Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
iA Global Asset Management
iA Global Asset Management Quebec, Quebec, Canada $8.54B AUM 39.73% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Parsons Capital Management
Parsons Capital Management Providence, Rhode Island $2.29B AUM 21.99% 1-Year Est. Return

Citigroup's AMLX Position: Q3 2026 in Review

Citigroup reduced its Amylyx Pharmaceuticals (AMLX) stake by 48% in Q3 2026, selling an estimated $870K and leaving 35,852 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3285.

Citigroup first reported a position in AMLX in Q1 2022 and has held it in 19 quarters since. The position peaked at $5.71M in Q4 2023. 50 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

  • Citigroup held 35,852 shares of Amylyx Pharmaceuticals worth $1.04M as of Q3 2026.
  • Citigroup sold 32,832 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $870K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3285 holding.
  • Citigroup first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 19 quarters since.
  • Citigroup's Amylyx Pharmaceuticals position peaked at $5.71M in Q4 2023.
  • 50 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.